L-DOPA treatment reverses the motor alterations induced by manganese exposure as a Parkinson disease experimental model.

Abstract This investigation was designed to determine whether l -DOPA treatment improves the motor alterations observed after divalent and trivalent manganese (Mn) mixture inhalation on mice to ensure that the alterations are of dopaminergic origin. CD-1 male mice inhaled a mixture of 0.04 M manganese chloride (MnCl 2 ) and manganese acetate (Mn(OAc) 3 ), 1 h twice a week for 5 months. Before Mn exposure, animals were trained to perform motor function tests and were evaluated each week after the exposure. Overall behavior was assessed by ratings and by videotaped analyses; by the end of Mn exposure period, 10 mice were orally treated with 7.5 mg/kg l -DOPA. After 5 months of Mn-mixture inhalation striatal dopamine content decreased 71%, mice developed evident deficits in motor performance manifested as akinesia, postural instability and action tremor; these alterations were reverted with l -DOPA treatment. Our results suggest that the motor alterations induced by the inhalation of the combination of MnCl 2 /Mn(OAc) 3 are related to nigrostriatal dopaminergic function providing new light on the understanding of manganese neurotoxicity as a suitable Parkinson disease experimental model.